Alivus Life
NSE: ALIVUS · Pharmaceuticals
Snapshot
Unlock Alivus Life's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alivus Life Sciences Limited is a pharmaceutical company that develops, manufactures, and markets a diverse portfolio of active pharmaceutical ingredients (APIs). The company serves global markets across therapeutic areas including cardiovascular health, oncology, diabetes, and central nervous system disorders.
Business Model
The company generates revenue through the sale of a broad range of APIs and by providing contract development and manufacturing services to multinational and specialty pharmaceutical corporations. It operates as a subsidiary of Nirma Limited and maintains an extensive international export network.
- Founded:2001
- Parent Company:Nirma Limited
Growth Outlook
Growth is driven by the expansion of its API portfolio and the strengthening of its contract development and manufacturing service offerings for global clients. The company continues to leverage its established manufacturing capabilities to cater to diverse international markets.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international quality standards and potential audits by global health authorities.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials and key starting materials can impact manufacturing margins.
- Geopolitical and Currency Risk. As a significant exporter, the company is exposed to currency exchange rate volatility and changing trade policies in international markets.
- Competitive Pricing. The global API market is highly competitive, which may exert downward pressure on product pricing and profitability.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Alivus Life and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,552 Cr
TTM · standalone
NET PROFIT
₹564 Cr
TTM · standalone
EPS
₹45.99
TTM · standalone
RETURN ON EQUITY
19.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
24.6%
TTM · standalone
P/E
25.3x
Q4 FY26 · standalone
EV/EBITDA
16.7x
Q4 FY26 · standalone
EBITDA MARGIN
33.6%
TTM · standalone
NET PROFIT MARGIN
23.6%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Alivus LifeALIVUS | 11,958 | 25.31 | 16.66 | 6.9% | 33.6% | 19.2% | 24.6% | +9.2% |
Alembic Pharmaceuticals Ltd.APLLTD | 13,129 | 24.47 | 15.07 | 10.1% | 16.0% | 12.6% | 14.2% | -18.1% |
Rubicon ResearchRUBICON | 12,884 | — | — | — | 23.0% | — | — | — |
Caplin Point Laboratories Ltd.CAPLIPOINT | 12,103 | 31.67 | 23.06 | 12.9% | 40.1% | 21.4% | 26.0% | +28.5% |
Cohance Lifesciences Ltd.COHANCE | 11,471 | 73.99 | 28.98 | 135.3% | 20.8% | 8.7% | 9.7% | -58.5% |
Concord Biotech Ltd.CONCORDBIO | 10,890 | 54.32 | 33.52 | -12.1% | 39.8% | 13.9% | 18.0% | -26.8% |
As of Q4 FY26
Financials
Alivus Life
NSE: ALIVUS · Pharmaceuticals
Snapshot
Unlock Alivus Life's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alivus Life Sciences Limited is a pharmaceutical company that develops, manufactures, and markets a diverse portfolio of active pharmaceutical ingredients (APIs). The company serves global markets across therapeutic areas including cardiovascular health, oncology, diabetes, and central nervous system disorders.
Business Model
The company generates revenue through the sale of a broad range of APIs and by providing contract development and manufacturing services to multinational and specialty pharmaceutical corporations. It operates as a subsidiary of Nirma Limited and maintains an extensive international export network.
- Founded:2001
- Parent Company:Nirma Limited
Growth Outlook
Growth is driven by the expansion of its API portfolio and the strengthening of its contract development and manufacturing service offerings for global clients. The company continues to leverage its established manufacturing capabilities to cater to diverse international markets.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international quality standards and potential audits by global health authorities.
- Supply Chain Volatility. Fluctuations in the cost and availability of raw materials and key starting materials can impact manufacturing margins.
- Geopolitical and Currency Risk. As a significant exporter, the company is exposed to currency exchange rate volatility and changing trade policies in international markets.
- Competitive Pricing. The global API market is highly competitive, which may exert downward pressure on product pricing and profitability.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Alivus Life and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,552 Cr
TTM · standalone
NET PROFIT
₹564 Cr
TTM · standalone
EPS
₹45.99
TTM · standalone
RETURN ON EQUITY
19.2%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
24.6%
TTM · standalone
P/E
25.3x
Q4 FY26 · standalone
EV/EBITDA
16.7x
Q4 FY26 · standalone
EBITDA MARGIN
33.6%
TTM · standalone
NET PROFIT MARGIN
23.6%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26